Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Librel NDA Accepted By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Wyeth expects a standard 10-month review for its continuous-use contraceptive; the NDA for the low-dose levonorgestrel/ethinyl estradiol product was submitted May 27

You may also be interested in...



Lybrel PDUFA Date Pushed Back Until June

Wyeth has submitted additional data requested by FDA to support its application for the oral contraceptive.

Lybrel PDUFA Date Pushed Back Until June

Wyeth has submitted additional data requested by FDA to support its application for the oral contraceptive.

Barr's Seasonique Is "Approvable" Pending Data On The Contraceptive's Regimen

The firm is seeking a meeting with FDA to discuss use of results from ongoing studies of the extended-regimen oral contraceptive.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel